Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than the preoperative setting.

Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates.